Generic Name and Formulations:
Nitroglycerin 0.1mg/hr, 0.2mg/hr, 0.3mg/hr, 0.4mg/hr, 0.6mg/hr, 0.8mg/hr; transdermal patches.
Merck & Co., Inc.
Indications for NITRO-DUR:
Prophylaxis of angina. Not for acute attacks.
Initially one 0.2–0.4mg/hr patch for 12–14hr/day. Remove patch for 10–12hrs/day.
Concomitant PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil), riociguat.
Acute MI. Volume depletion. Hypotension. Heart failure. Hypertrophic cardiomyopathy. Reduce dose if hypotension occurs. Remove before defibrillation or cardioversion. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with PDE-5 inhibitors, riociguat. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, increased angina, lightheadedness, syncope, orthostatic hypotension, tachycardia, rash.
Endocrinology Advisor Articles
- Fasting Glycemic Variability Indicates Increased Risk for Type 2 Diabetes
- Heritability of BMI Stronger in Obesogenic Environments
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality
- Vitamin D Supplementation Has No Effect on Musculoskeletal Health
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Industry-Funded Trials Often Involve Employees in Studies
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Early-Onset Asthma/Wheezing Associated With Later Childhood Obesity